Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Fancy who wrote (5905)	1/20/1999 12:31:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 6136

I think that the acquisition/merger issue is as much in the how much category, as it is in the if or when category. On Nov 6 Bear Stearns downgraded AGPH (which was at $41) because they thought that the buyout would not have much of a premium: biocognizance.com Not sure if the market is beginning to believe BS, some news is coming up (AIDS and Infectious Disease Conference begins at the end of this month), or some are taking profits.